Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2025-04-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of the company's internal control over financial reporting as of December 31, 2024. The content focuses on the auditor's responsibility, the company's responsibility, and the auditor's opinion on internal control effectiveness. It does not contain full financial statements or comprehensive annual or interim report data. The document is a standalone audit report on internal controls, not a full annual report or interim report. Therefore, it fits the category of Audit Report / Information (AR). The document length is 751 characters, indicating it is a concise report rather than an announcement or certification letter. Hence, the classification is AR with high confidence. FY 2024
2025-04-24 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' or 'Crisis Management Policy'. It outlines the company's internal policies and procedures for managing public opinion, media relations, and crisis communication, including organizational structure, responsibilities, principles, and accountability. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no capital changes, no legal proceedings, no executive changes, no earnings announcements, or any other typical financial or regulatory report content. The document is a governance-related internal policy document approved by the board. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2884 characters, which is consistent with a policy document rather than a full financial report or announcement.
2025-04-24 Chinese
关于2024年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the provision for asset impairment for the fiscal year 2024. It details the amounts and types of impairment losses recognized, the accounting policies applied, and the impact on financial results. It includes board and supervisory committee opinions on the reasonableness of the impairment provision. The document is relatively short (2480 characters) and focuses on a specific accounting event rather than presenting a full financial report or comprehensive financial statements. It does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of a report publication but a substantive disclosure about asset impairment. Given the nature of the content, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2025-04-24 Chinese
2024年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 成都市贝瑞和康基因技术股份有限公司, issued by a registered accounting firm. It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and accounts receivable impairment, responsibilities of management and auditors, and extensive accounting policies and notes. The document includes financial statement audit details for the fiscal year ending December 31, 2024, and is signed and dated April 23, 2025. The content is consistent with a standalone audit report rather than a full annual report or other filing types. It is not a brief announcement or certification but a comprehensive audit report document. FY 2024
2025-04-24 Chinese
董事会审计委员会对会计师事务所2024年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the accounting firm for the 2024 fiscal year. It details the auditor's qualifications, audit scope, and the committee's supervision activities related to the audit of the company's 2024 annual financial report. The document does not contain the actual audited financial statements or detailed financial data but rather an assessment and oversight report on the auditor's work and independence. It is not the annual report itself, nor is it a certification or a brief announcement. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit firms' performance and internal control audits, excluding full annual reports. FY 2024
2025-04-24 Chinese
关于全资子公司与首都医科大学附属北京儿童医院签署《项目成果转化合作框架协议》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company about signing a cooperation framework agreement between its wholly-owned subsidiary and a hospital for a project on clinical technology research and product development. It details the parties involved, the purpose and content of the cooperation, the impact on the company, risk warnings, and related disclosures. The document is relatively short (2705 characters) and does not contain any financial statements, audit information, or detailed financial data. It is not a report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about a business cooperation agreement, which does not fall under categories like M&A, capital changes, or management changes. It is a typical regulatory filing announcing a material cooperation agreement and related information. Therefore, the best fitting category is Regulatory Filings (RNS).
2025-04-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.